M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
A milestone for Tmalin
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
US shutdown freezes new drug applications
Key FDA decisions are expected to face delays.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Astra's clash of the T-cell engager Titans
The Titan CD8-guiding technology seems to have spawned a new variant.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
FDA red and green lights: September 2025
A single-arm trial was enough for J&J’s Inlexzo nod.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
The month ahead: October’s upcoming events
ESMO and the Triple Meeting approach.
